Despite crashing by over 75% in 2011, XOMA is up 165% this year, putting it at #20 on our list of the very best healthcare stocks for investors in 2012.
Celldex's new drug uses an advanced new delivery system to reach tumors, and investors are pleased; the stock is up 20% today.
Friday's FDA advisory committee ruling against Zogenix's painkiller Zohydro has caused shares to tank.
Medical robot company MAKO Surgical makes No. 10 on our list of the very worst stocks in the healthcare sector this year.
A new approval for Bristol-Myers Squibb means important access to the UK market for its arthritis drug. But can the company shake a few persistent old problems?
Moody's just upgraded this diabetes juggernaut's already sublime credit rating.
The next hot drug area may surprise you.
Johnson & Johnson is passing the torch to a new chairman.
An historically difficult area to treat, big names are competing to be the first to crack the Alzheimer's code. Here's the newest big name on that list.
Losing a staggering 52.8% of its share price this year, pharmaceutical company ArQule is No. 6 on our list of the very worst healthcare stocks of 2012.
The first company on our list that's down over 50% this year, with a loss of 50.8% is Quality Systems, in at #7 on our list of the very worst health care stocks of the year.
With a 48.1% loss this year, Accretive Health lands at No. 8 on our countdown of the very worst healthcare stocks of 2012.
Delcath's drop of 47.2% puts it at No. 9 on our list of the very worst healthcare stocks of the year.
At No. 21 on our list of the very worst healthcare stocks of 2012, Questcor Pharmaceuticals.
As we continue the countdown of the worst stocks in healthcare for 2012, we look at No. 22 on the list, Horizon Pharmaceuticals.
Universal American Corporation is No. 23 on our list of the worst healthcare stocks of 2012.
A look at the very worst healthcare stocks this year. At No. 24, Halozyme Therapeutics.
Trius Therapeutics kicks off our naughty list for the worst health care stocks of 2012.
This major operator of health-care facilities is paying out yet another special dividend.
With shares up more than 50% over the past five trading sessions on largely no news, what does this biotech have up its sleeve?